Menu

Filtros : "Cardiovascular Drugs and Therapy" Limpar

Filtros

Refine with date range

  • 1

1 - 10 (10 records)

  • Artigo de periodico

    Reduction of atherosclerotic lesions by the chemotherapeutic agent carmustine associated to lipid nanoparticles (2016)

    Daminelli, Elaine N; Martinelli, Ana E. M; Bulgarelli, Adriana; Freitas, Fatima R; Maranhão, Raul Cavalcante

    Source: Cardiovascular Drugs and Therapy. Unidade: FCF

    Subjects: ARTERIOSCLEROSE, NANOPARTÍCULAS, COLESTEROL

    Acesso à fonteDOIHow to cite
    A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas

    • ABNT

      DAMINELLI, Elaine N et al. Reduction of atherosclerotic lesions by the chemotherapeutic agent carmustine associated to lipid nanoparticles. Cardiovascular Drugs and Therapy, v. 30, n. 5, p. 433-443, 2016Tradução . . Disponível em: https://doi.org/10.1007/s10557-016-6675-0. Acesso em: 14 maio 2024.

    • APA

      Daminelli, E. N., Martinelli, A. E. M., Bulgarelli, A., Freitas, F. R., & Maranhão, R. C. (2016). Reduction of atherosclerotic lesions by the chemotherapeutic agent carmustine associated to lipid nanoparticles. Cardiovascular Drugs and Therapy, 30( 5), 433-443. doi:10.1007/s10557-016-6675-0

    • NLM

      Daminelli EN, Martinelli AEM, Bulgarelli A, Freitas FR, Maranhão RC. Reduction of atherosclerotic lesions by the chemotherapeutic agent carmustine associated to lipid nanoparticles [Internet]. Cardiovascular Drugs and Therapy. 2016 ; 30( 5): 433-443.[citado 2024 maio 14 ] Available from: https://doi.org/10.1007/s10557-016-6675-0

    • Vancouver

      Daminelli EN, Martinelli AEM, Bulgarelli A, Freitas FR, Maranhão RC. Reduction of atherosclerotic lesions by the chemotherapeutic agent carmustine associated to lipid nanoparticles [Internet]. Cardiovascular Drugs and Therapy. 2016 ; 30( 5): 433-443.[citado 2024 maio 14 ] Available from: https://doi.org/10.1007/s10557-016-6675-0

  • Artigo de periodico

    Use of combined chemotherapy with etoposide and methotrexate, both associated to lipid nanoemulsions for atherosclerosis treatment in cholesterol-fed rabbits (2015)

    Leite Junior, Antonio Carlos de Arruda; Solano, Tatiana V; Tavares, Elaine Rufo; Maranhão, Raul Cavalcante

    Source: Cardiovascular Drugs and Therapy. Unidade: FCF

    Subjects: QUIMIOTERAPIA COMBINADA, ARTERIOSCLEROSE, NANOPARTÍCULAS, COLESTEROL

    Acesso à fonteDOIHow to cite
    A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas

    • ABNT

      LEITE JUNIOR, Antonio Carlos de Arruda et al. Use of combined chemotherapy with etoposide and methotrexate, both associated to lipid nanoemulsions for atherosclerosis treatment in cholesterol-fed rabbits. Cardiovascular Drugs and Therapy, v. 29, n. 1, p. . 15-22, 2015Tradução . . Disponível em: https://doi.org/10.1007/s10557-014-6566-1. Acesso em: 14 maio 2024.

    • APA

      Leite Junior, A. C. de A., Solano, T. V., Tavares, E. R., & Maranhão, R. C. (2015). Use of combined chemotherapy with etoposide and methotrexate, both associated to lipid nanoemulsions for atherosclerosis treatment in cholesterol-fed rabbits. Cardiovascular Drugs and Therapy, 29( 1), . 15-22. doi:10.1007/s10557-014-6566-1

    • NLM

      Leite Junior AC de A, Solano TV, Tavares ER, Maranhão RC. Use of combined chemotherapy with etoposide and methotrexate, both associated to lipid nanoemulsions for atherosclerosis treatment in cholesterol-fed rabbits [Internet]. Cardiovascular Drugs and Therapy. 2015 ; 29( 1): . 15-22.[citado 2024 maio 14 ] Available from: https://doi.org/10.1007/s10557-014-6566-1

    • Vancouver

      Leite Junior AC de A, Solano TV, Tavares ER, Maranhão RC. Use of combined chemotherapy with etoposide and methotrexate, both associated to lipid nanoemulsions for atherosclerosis treatment in cholesterol-fed rabbits [Internet]. Cardiovascular Drugs and Therapy. 2015 ; 29( 1): . 15-22.[citado 2024 maio 14 ] Available from: https://doi.org/10.1007/s10557-014-6566-1

  • Artigo de periodico

    Altered microRNome profiling in statin-induced HepG2 Cells: a pilot study identifying potential new biomarkers involved in lipid-lowering treatment (2015)

    Zambrano, Tomás; Hirata, Rosario Dominguez Crespo ; Hirata, Mario Hiroyuki ; Cerda, Alvaro; Salazar, Luis A

    Source: Cardiovascular Drugs and Therapy. Unidade: FCF

    Subjects: COLESTEROL, BIOMARCADORES, LIPÍDEOS

    Acesso à fonteDOIHow to cite
    A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas

    • ABNT

      ZAMBRANO, Tomás et al. Altered microRNome profiling in statin-induced HepG2 Cells: a pilot study identifying potential new biomarkers involved in lipid-lowering treatment. Cardiovascular Drugs and Therapy, v. 29, n. 6, p. 509-518, 2015Tradução . . Disponível em: https://doi.org/10.1007/s10557-015-6627-0. Acesso em: 14 maio 2024.

    • APA

      Zambrano, T., Hirata, R. D. C., Hirata, M. H., Cerda, A., & Salazar, L. A. (2015). Altered microRNome profiling in statin-induced HepG2 Cells: a pilot study identifying potential new biomarkers involved in lipid-lowering treatment. Cardiovascular Drugs and Therapy, 29( 6), 509-518. doi:10.1007/s10557-015-6627-0

    • NLM

      Zambrano T, Hirata RDC, Hirata MH, Cerda A, Salazar LA. Altered microRNome profiling in statin-induced HepG2 Cells: a pilot study identifying potential new biomarkers involved in lipid-lowering treatment [Internet]. Cardiovascular Drugs and Therapy. 2015 ; 29( 6): 509-518.[citado 2024 maio 14 ] Available from: https://doi.org/10.1007/s10557-015-6627-0

    • Vancouver

      Zambrano T, Hirata RDC, Hirata MH, Cerda A, Salazar LA. Altered microRNome profiling in statin-induced HepG2 Cells: a pilot study identifying potential new biomarkers involved in lipid-lowering treatment [Internet]. Cardiovascular Drugs and Therapy. 2015 ; 29( 6): 509-518.[citado 2024 maio 14 ] Available from: https://doi.org/10.1007/s10557-015-6627-0

  • Artigo de periodico

    Anti-atherogenic effects of methotrexate carried by a lipid nanoemulsion that binds to LDL receptors in cholesterol-fed rabbits (2013)

    Bulgarelli, Adriana; Leite Junior, Antonio Carlos de Arruda; Dias, Adriana Abalen Martins; Maranhão, Raul Cavalcante

    Source: Cardiovascular Drugs and Therapy. Unidade: FCF

    Subjects: LIPOPROTEÍNAS LDL, ARTRITE REUMATOIDE, INFLAMAÇÃO

    Acesso à fonteDOIHow to cite
    A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas

    • ABNT

      BULGARELLI, Adriana et al. Anti-atherogenic effects of methotrexate carried by a lipid nanoemulsion that binds to LDL receptors in cholesterol-fed rabbits. Cardiovascular Drugs and Therapy, v. 27, n. 6, p. 531-539, 2013Tradução . . Disponível em: https://doi.org/10.1007/s10557-013-6488-3. Acesso em: 14 maio 2024.

    • APA

      Bulgarelli, A., Leite Junior, A. C. de A., Dias, A. A. M., & Maranhão, R. C. (2013). Anti-atherogenic effects of methotrexate carried by a lipid nanoemulsion that binds to LDL receptors in cholesterol-fed rabbits. Cardiovascular Drugs and Therapy, 27( 6), 531-539. doi:10.1007/s10557-013-6488-3

    • NLM

      Bulgarelli A, Leite Junior AC de A, Dias AAM, Maranhão RC. Anti-atherogenic effects of methotrexate carried by a lipid nanoemulsion that binds to LDL receptors in cholesterol-fed rabbits [Internet]. Cardiovascular Drugs and Therapy. 2013 ; 27( 6): 531-539.[citado 2024 maio 14 ] Available from: https://doi.org/10.1007/s10557-013-6488-3

    • Vancouver

      Bulgarelli A, Leite Junior AC de A, Dias AAM, Maranhão RC. Anti-atherogenic effects of methotrexate carried by a lipid nanoemulsion that binds to LDL receptors in cholesterol-fed rabbits [Internet]. Cardiovascular Drugs and Therapy. 2013 ; 27( 6): 531-539.[citado 2024 maio 14 ] Available from: https://doi.org/10.1007/s10557-013-6488-3

  • Artigo de periodico

    Doxycycline prevents acute pulmonary embolism-induced mortality and right ventricular deformation in rats (2013)

    Cáu, Stêfany Bruno de Assis; Barato, Renan C.; Celes, Mara Rúbia Nunes; Muniz, Jaqueline J.; Rossi, Marcos Antonio; Tanus-Santos, José Eduardo

    Source: Cardiovascular Drugs and Therapy. Unidade: FMRP

    Subjects: EMBOLIA PULMONAR, DOENÇAS CARDIOVASCULARES, METALOPROTEINASES, MODELOS ANIMAIS

    Acesso à fonteDOIHow to cite
    A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas

    • ABNT

      CÁU, Stêfany Bruno de Assis et al. Doxycycline prevents acute pulmonary embolism-induced mortality and right ventricular deformation in rats. Cardiovascular Drugs and Therapy, v. 27, n. 4, p. 259-267, 2013Tradução . . Disponível em: https://doi.org/10.1007/s10557-013-6458-9. Acesso em: 14 maio 2024.

    • APA

      Cáu, S. B. de A., Barato, R. C., Celes, M. R. N., Muniz, J. J., Rossi, M. A., & Tanus-Santos, J. E. (2013). Doxycycline prevents acute pulmonary embolism-induced mortality and right ventricular deformation in rats. Cardiovascular Drugs and Therapy, 27( 4), 259-267. doi:10.1007/s10557-013-6458-9

    • NLM

      Cáu SB de A, Barato RC, Celes MRN, Muniz JJ, Rossi MA, Tanus-Santos JE. Doxycycline prevents acute pulmonary embolism-induced mortality and right ventricular deformation in rats [Internet]. Cardiovascular Drugs and Therapy. 2013 ; 27( 4): 259-267.[citado 2024 maio 14 ] Available from: https://doi.org/10.1007/s10557-013-6458-9

    • Vancouver

      Cáu SB de A, Barato RC, Celes MRN, Muniz JJ, Rossi MA, Tanus-Santos JE. Doxycycline prevents acute pulmonary embolism-induced mortality and right ventricular deformation in rats [Internet]. Cardiovascular Drugs and Therapy. 2013 ; 27( 4): 259-267.[citado 2024 maio 14 ] Available from: https://doi.org/10.1007/s10557-013-6458-9

  • Artigo de periodico

    Angiotensin II Type 2 Receptor (AT2R) is associated with increased tolerance of the hyperthyroid heart to ischemia-reperfusion (2013)

    Tavares, Felix Meira; Silva, Ivson Bezerra da; Gomes, Dayane Aparecida; Barreto-Chaves, Maria Luiza Morais

    Source: Cardiovascular Drugs and Therapy. Unidade: ICB

    Assunto: ANATOMIA

    Acesso à fonteDOIHow to cite
    A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas

    • ABNT

      TAVARES, Felix Meira et al. Angiotensin II Type 2 Receptor (AT2R) is associated with increased tolerance of the hyperthyroid heart to ischemia-reperfusion. Cardiovascular Drugs and Therapy, v. 27, n. 5, p. 393-402, 2013Tradução . . Disponível em: https://doi.org/10.1007/s10557-013-6473-x. Acesso em: 14 maio 2024.

    • APA

      Tavares, F. M., Silva, I. B. da, Gomes, D. A., & Barreto-Chaves, M. L. M. (2013). Angiotensin II Type 2 Receptor (AT2R) is associated with increased tolerance of the hyperthyroid heart to ischemia-reperfusion. Cardiovascular Drugs and Therapy, 27( 5), 393-402. doi:10.1007/s10557-013-6473-x

    • NLM

      Tavares FM, Silva IB da, Gomes DA, Barreto-Chaves MLM. Angiotensin II Type 2 Receptor (AT2R) is associated with increased tolerance of the hyperthyroid heart to ischemia-reperfusion [Internet]. Cardiovascular Drugs and Therapy. 2013 ; 27( 5): 393-402.[citado 2024 maio 14 ] Available from: https://doi.org/10.1007/s10557-013-6473-x

    • Vancouver

      Tavares FM, Silva IB da, Gomes DA, Barreto-Chaves MLM. Angiotensin II Type 2 Receptor (AT2R) is associated with increased tolerance of the hyperthyroid heart to ischemia-reperfusion [Internet]. Cardiovascular Drugs and Therapy. 2013 ; 27( 5): 393-402.[citado 2024 maio 14 ] Available from: https://doi.org/10.1007/s10557-013-6473-x

  • Artigo de periodico

    Comprehensive evaluation of the effects of enalapril on matrix metalloproteinases levels in hypertension (2012)

    Fontana, Vanessa; Silva, Pamela S.; Izidoro-Toledo, Tatiane C.; Biagi, Celso; Oliveira, Eduardo Brandt de; Gerlach, Raquel Fernanda; Tanus-Santos, José Eduardo

    Source: Cardiovascular Drugs and Therapy. Unidades: FMRP, FORP

    Subjects: ANGIOTENSINAS, METALOPROTEINASES, HIPERTENSÃO

    Acesso à fonteDOIHow to cite
    A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas

    • ABNT

      FONTANA, Vanessa et al. Comprehensive evaluation of the effects of enalapril on matrix metalloproteinases levels in hypertension. Cardiovascular Drugs and Therapy, v. 26, n. 6, p. 511-519, 2012Tradução . . Disponível em: https://doi.org/10.1007/s10557-012-6420-2. Acesso em: 14 maio 2024.

    • APA

      Fontana, V., Silva, P. S., Izidoro-Toledo, T. C., Biagi, C., Oliveira, E. B. de, Gerlach, R. F., & Tanus-Santos, J. E. (2012). Comprehensive evaluation of the effects of enalapril on matrix metalloproteinases levels in hypertension. Cardiovascular Drugs and Therapy, 26( 6), 511-519. doi:10.1007/s10557-012-6420-2

    • NLM

      Fontana V, Silva PS, Izidoro-Toledo TC, Biagi C, Oliveira EB de, Gerlach RF, Tanus-Santos JE. Comprehensive evaluation of the effects of enalapril on matrix metalloproteinases levels in hypertension [Internet]. Cardiovascular Drugs and Therapy. 2012 ; 26( 6): 511-519.[citado 2024 maio 14 ] Available from: https://doi.org/10.1007/s10557-012-6420-2

    • Vancouver

      Fontana V, Silva PS, Izidoro-Toledo TC, Biagi C, Oliveira EB de, Gerlach RF, Tanus-Santos JE. Comprehensive evaluation of the effects of enalapril on matrix metalloproteinases levels in hypertension [Internet]. Cardiovascular Drugs and Therapy. 2012 ; 26( 6): 511-519.[citado 2024 maio 14 ] Available from: https://doi.org/10.1007/s10557-012-6420-2

  • Artigo de periodico

    Role of oral blockade of platelet glycoprotein IIb/IIIa on neutrophil activation in patients with acute coronary syndromes (2003)

    Serrano Junior, Carlos Vicente; Nicolau, José C.; Venturinelli, Margareth; Baracioli, Luciano P.; Anders, Robert J.; Cannon, Christopher P.; Ramires, José A. F.

    Source: Cardiovascular Drugs and Therapy. Unidade: FM

    Subjects: FARMACOLOGIA CLÍNICA, CARDIOPATIAS

    How to cite
    A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas

    • ABNT

      SERRANO JUNIOR, Carlos Vicente et al. Role of oral blockade of platelet glycoprotein IIb/IIIa on neutrophil activation in patients with acute coronary syndromes. Cardiovascular Drugs and Therapy, v. 17, p. 129-132, 2003Tradução . . Acesso em: 14 maio 2024.

    • APA

      Serrano Junior, C. V., Nicolau, J. C., Venturinelli, M., Baracioli, L. P., Anders, R. J., Cannon, C. P., & Ramires, J. A. F. (2003). Role of oral blockade of platelet glycoprotein IIb/IIIa on neutrophil activation in patients with acute coronary syndromes. Cardiovascular Drugs and Therapy, 17, 129-132.

    • NLM

      Serrano Junior CV, Nicolau JC, Venturinelli M, Baracioli LP, Anders RJ, Cannon CP, Ramires JAF. Role of oral blockade of platelet glycoprotein IIb/IIIa on neutrophil activation in patients with acute coronary syndromes. Cardiovascular Drugs and Therapy. 2003 ; 17 129-132.[citado 2024 maio 14 ]

    • Vancouver

      Serrano Junior CV, Nicolau JC, Venturinelli M, Baracioli LP, Anders RJ, Cannon CP, Ramires JAF. Role of oral blockade of platelet glycoprotein IIb/IIIa on neutrophil activation in patients with acute coronary syndromes. Cardiovascular Drugs and Therapy. 2003 ; 17 129-132.[citado 2024 maio 14 ]

  • Artigo de periodico

    Ajmaline test as a method to diselose latent experimental chagas heart disease (1989)

    Bestetti, Reinaldo Bulgarelli; Soares, E G; Sales Neto, V N; Oliveira, João Samuel Meira de

    Source: Cardiovascular Drugs and Therapy. Unidades: FMRP, COSEAS

    Assunto: CARDIOLOGIA

    How to cite
    A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas

    • ABNT

      BESTETTI, Reinaldo Bulgarelli et al. Ajmaline test as a method to diselose latent experimental chagas heart disease. Cardiovascular Drugs and Therapy, v. 3 , p. 171-6, 1989Tradução . . Acesso em: 14 maio 2024.

    • APA

      Bestetti, R. B., Soares, E. G., Sales Neto, V. N., & Oliveira, J. S. M. de. (1989). Ajmaline test as a method to diselose latent experimental chagas heart disease. Cardiovascular Drugs and Therapy, 3 , 171-6.

    • NLM

      Bestetti RB, Soares EG, Sales Neto VN, Oliveira JSM de. Ajmaline test as a method to diselose latent experimental chagas heart disease. Cardiovascular Drugs and Therapy. 1989 ;3 171-6.[citado 2024 maio 14 ]

    • Vancouver

      Bestetti RB, Soares EG, Sales Neto VN, Oliveira JSM de. Ajmaline test as a method to diselose latent experimental chagas heart disease. Cardiovascular Drugs and Therapy. 1989 ;3 171-6.[citado 2024 maio 14 ]

  • Artigo de periodico

    Isoproterenol induced rat cardiomyopathy: an electrocardiographic pathology study (1987)

    Bestetti, Reinaldo Bulgarelli; Ramos, C P; Silva, J. F.; Salles Netto, F N; Soares, E G; Oliveira, João Samuel Meira de

    Source: Cardiovascular Drugs and Therapy. Unidades: FMRP, COSEAS

    Assunto: CARDIOLOGIA

    How to cite
    A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas

    • ABNT

      BESTETTI, Reinaldo Bulgarelli et al. Isoproterenol induced rat cardiomyopathy: an electrocardiographic pathology study. Cardiovascular Drugs and Therapy, v. 1 , p. 215, 1987Tradução . . Acesso em: 14 maio 2024.

    • APA

      Bestetti, R. B., Ramos, C. P., Silva, J. F., Salles Netto, F. N., Soares, E. G., & Oliveira, J. S. M. de. (1987). Isoproterenol induced rat cardiomyopathy: an electrocardiographic pathology study. Cardiovascular Drugs and Therapy, 1 , 215.

    • NLM

      Bestetti RB, Ramos CP, Silva JF, Salles Netto FN, Soares EG, Oliveira JSM de. Isoproterenol induced rat cardiomyopathy: an electrocardiographic pathology study. Cardiovascular Drugs and Therapy. 1987 ;1 215.[citado 2024 maio 14 ]

    • Vancouver

      Bestetti RB, Ramos CP, Silva JF, Salles Netto FN, Soares EG, Oliveira JSM de. Isoproterenol induced rat cardiomyopathy: an electrocardiographic pathology study. Cardiovascular Drugs and Therapy. 1987 ;1 215.[citado 2024 maio 14 ]
  • 1

1 - 10 (10 records)

Digital Library of Intellectual Production of Universidade de São Paulo     2012 - 2024